290 related articles for article (PubMed ID: 16470950)
1. Trastuzumab in breast cancer.
Gounaris IG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
[No Abstract] [Full Text] [Related]
2. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
3. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
4. Trastuzumab in breast cancer.
Banna GL; Santoro A
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
[No Abstract] [Full Text] [Related]
5. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
6. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
7. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
8. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
9. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
10. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
11. [Very small breast cancer, HER2 positive, and trastuzumab in adjuvant treatment].
Vyzula R
Klin Onkol; 2010; 23(1):21-4. PubMed ID: 20192070
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM; Myatt CV; Perez EA
Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
[TBL] [Abstract][Full Text] [Related]
14. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
16. Trastuzumab faces trials, clinical and otherwise.
Tuma RS
J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
[No Abstract] [Full Text] [Related]
17. Continuation of trastuzumab beyond disease progression.
Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
[No Abstract] [Full Text] [Related]
18. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
19. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy for breast cancer and targeted therapies].
Dufresne A; Bachelot T; Blay JY
Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
[No Abstract] [Full Text] [Related]
[Next] [New Search]